Video

New Delivery Option for Ketamine

Author(s):

Jeffrey Becker, MD

How can new formulations of ketamine impact patient care?

Current Time 0:00
Duration 7:31
Loaded: 0%
Stream Type LIVE
Remaining Time 7:31
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
    • en (Main), selected

    Jeffrey Becker, MD, discusses new formulations of ketamine for subcutaneous delivery and how ketamine works.

    Dr Becker is cofounder and Chief Scientific Officer at Bexson Biomedical, Inc.

    Related Videos
    “What we’re striving to do is conquer the unmet needs that are still here with treating ADHD, especially from a medication standpoint.”
    Optimizing Treatment for ADHD
    New Biomarker Study of Rapid-Acting Treatment for Acute Depression
    New Biomarker Study of Rapid-Acting Treatment for Acute Depression
    “If You Ask Me My Name”
    “If You Ask Me My Name”
    New Year, New Look
    New Year, New Look
    Work takes up one-third of a patient’s life—it is important that we pay attention to it.
    Taking and Leveraging In-Depth Work Histories: Educating the Future of Psychiatry
    An American Sunrise
    An American Sunrise
    How Full is Your New Year Glass This Year?
    How Full is Your New Year Glass This Year?
    A new treatment in development is poised to be a game-changer for patients with postpartum depression.
    Clinical Advances in Treating PPD on the Horizon
    An expert discusses the latest on EndeavorRx and more digital therapeutics for this patient population.
    Digital Therapeutics for the Treatment of ADHD in Children
    Holiday Mental Health Tips From Santa
    Holiday Mental Health Tips From Santa
    Related Content
    How effective are these agents for AUD treatment? An expert shares highlights from his 2024 ASCP Annual Meeting Pharmaceutical Pipeline Update presentation.
    June 5th 2024

    An Update on GLP-1 Receptor Agonists as Pharmacotherapies for AUD

    Mehdi Farokhnia, MD, MPH
    Erin Crown, MHS, PA-C, shares her thoughts on ASCP, the annual meeting, and more.
    May 30th 2024

    Research and Opportunities at the 2024 ASCP Annual Meeting

    Erin Crown, MHS, PA-C, Psych-CAQ
    Anita H. Clayton, MD, gives a preview of her upcoming poster presentation at the 2024 ASCP Annual Meeting.
    May 30th 2024

    Early Improvement of Symptoms in Bipolar 1 Depression

    Anita H. Clayton, MD
    Joseph F. Goldberg, MD, gives a preview of his upcoming panel presentation at the 2024 ASCP Annual Meeting.
    May 30th 2024

    Pseudospecific and Transdiagnostic Symptom Targeting in Clinical Trials

    Joseph F. Goldberg, MD
    Anita H. Clayton, MD, welcomes us all to the 2024 ASCP Annual Meeting!
    May 29th 2024

    Exciting Possibilities at ASCP 2024

    Anita H. Clayton, MD
    An expert shares highlights from her panel presentation at the 2024 ASCP Annual Meeting.
    May 28th 2024

    Navigating New Treatments for PTSD

    Lori Davis, MD
    © 2025 MJH Life Sciences

    All rights reserved.